LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at the opening of trading on July 15, 2026, following FINRA approval. The corporate action, combined with a mandatory share exchange and new CUSIP number (21116R404), is designed to increase the number of outstanding shares and potentially improve liquidity and accessibility for investors. The temporary trading symbol LMEDD will revert to LMED after approximately 20 business days.
The forward stock split reflects the Company's efforts to align its capital structure with long-term growth objectives. Dr. Kevin Rodan Levy, CEO, stated that the milestone supports LataMed's focus on expanding its telemedicine platform and pursuing commercialization of its artificial intelligence platforms, including CardioAI, PulmoAI, and NeuroAI. These technologies target healthcare challenges in emerging markets, particularly Latin America, by enhancing diagnostic capabilities and healthcare coordination.
Shareholders holding shares through brokerage accounts or in electronic book-entry form do not need to take action, as the split will be processed automatically. Those with physical stock certificates are not required to surrender them immediately but will receive post-split shares under the new CUSIP when they transfer, sell, or exchange them. The Company advises shareholders with questions to contact their brokerage firm or its transfer agent.
This corporate action comes as LataMed AI develops telehealth infrastructure and AI-enabled solutions for underserved regions. The forward split may signal confidence in the Company's strategic direction, though it does not change the underlying value of the business. Investors are encouraged to review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov and visit the Company's website at https://latamed.ai for more information.
The forward-looking statements in the press release highlight risks including the Company's ability to implement its business plan, secure financing, obtain regulatory approvals, and commercialize its platforms. LataMed AI undertakes no obligation to update these statements except as required by law.
